SCHEMBL3774069

SCHEMBL3774069

CCCc1ccc(C(=O)NC2CCN(CC(=O)N3CCN(C4CCC4)CC3)CC2)cc1

nearest known ligand 0.57

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.57
HRH3 Q9Y5N1 3/20 0.45
ALDH1A1 P00352 2/20 0.44
TSHR P16473 1/20 0.44
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
F10 P00742 1/20 0.43
OPRK1 P41145 1/20 0.43
LMNA P02545 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
MEN1 O00255 1/20 0.42
TP53 P04637 1/20 0.42
SLC6A5 Q9Y345 3/20 0.42
KDM4E B2RXH2 1/20 0.42
CHRM2 P08172 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3771229 0.94 KMT2A (0.50) KMT2AHRH3ALDH1A1TSHROPRK1
SCHEMBL3773424 0.88 KMT2A (0.61) KMT2AHRH3ALDH1A1TSHRNPC1
SCHEMBL3762894 0.85 KMT2A (0.57) KMT2AALDH1A1TSHRLMNAMEN1
SCHEMBL3770279 0.85 KMT2A (0.56) KMT2AHRH3ALDH1A1TSHRNPC1
SCHEMBL3780450 0.85 KMT2A (0.64) KMT2AHRH3ALDH1A1OPRK1MEN1
SCHEMBL3779305 0.85 KMT2A (0.58) KMT2AHRH3NPC1RAB9AF10
SCHEMBL13006775 0.85 KMT2A (0.79) KMT2AHRH3ALDH1A1TSHRF10
SCHEMBL3760993 0.85 KMT2A (0.58) KMT2AHRH3ALDH1A1NPC1RAB9A
SCHEMBL3772494 0.84 HRH3 (0.57) KMT2AHRH3ALDH1A1TSHRKDM4E
SCHEMBL3768221 0.84 KMT2A (0.56) KMT2AHRH3ALDH1A1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
WO-2007016496-A2 DIPIPERAZINYL KETONES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049571-A1 Dipiperazinyl ketones and related analogues HRH4, HRH3, HRH1 KMT2A 242/4885HRH3 2/4885ALDH1A1 1210/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.